Healthcare

PRODUCTS

  • GettyImages-1418357339-hand-spreadsheet-computer-keyboard
    Electronic Data Capture (EDC) System: Leverage Flexibility And Speed

    Neither traditional nor hybrid clinical trials can operate on rigid EDC systems.

    They require flexible data collection systems that support protocol amendments without downtime and accept mobile data without hassle. As a cloud-native solution, TrialKit bends to accommodate mid-study changes. And as the first full-featured EDC platform available as a native mobile app, TrialKit flexes to meet the demands of traditional, hybrid/decentralized, and completely remote clinical trials.

    Give your team the freedom to build, deploy, and manage their studies, their way—weeks faster than with rigid EDCs and for a fraction of the cost of the major players.

  • Data Folder
    Production Lifecycle, Bioprocess R&D, Scale-Up, Tech Transfer, Validation, And Mfg

    Werum PAS-X Savvy accelerates bioprocessing with real-time data management, visualization, and analysis—enabling agile development, robust decision-making, cost reduction, and consistent quality across pharma and biotech production lifecycles.

  • iMednet EDC
    Streamline Electronic Data Capture With iMednet EDC

    At the core of our comprehensive eClinical platform, iMednet EDC is uniquely designed to help sponsors and CROs achieve their clinical research goals. Highly flexible, it enables you to build studies quickly, while easily adapting to complex protocols and mid-study changes with ease.

  • Scientist Research Data GettyImages-1140779713
    End-To-End Data Management Services

    Avance Clinical’s data management team has gained a world-class reputation for accuracy, precision, and quality of their biostatistics and pharmacokinetic (PK) analysis.

  • GettyImages-849207658 Drug toxicity concept
    NDA Submissions 505(b)(1) Or 505(b)(2)

    There are clearly defined pathways for drug approval, and choosing the right regulatory pathway for your drug development program requires a thorough understanding of sections 505(b)(1) and 505(b)(2) of the Federal Food, Drug, and Cosmetics (FD&C) Act.

WHITE PAPERS AND CASE STUDIES

NEWS